Eupraxia Pharmaceuticals (EPRX) Receivables (2022 - 2025)

Eupraxia Pharmaceuticals (EPRX) has 4 years of Receivables data on file, last reported at $1.4 million in Q4 2025.

• On a quarterly basis, Receivables rose 185.52% year-over-year to $1.4 million in Q4 2025; TTM through Dec 2025 was $1.4 million, a 185.52% increase from a year earlier, with the FY2025 full-year figure at $1.4 million, up 185.52% from the prior year.
• Receivables for Q4 2025 stood at $1.4 million, up from $486946.0 in the prior quarter.
• Over the last five years, Receivables for EPRX reached as high as $1.4 million in Q4 2025 and fell as low as $103607.0 in Q4 2022.
• Historically, Receivables has averaged $581308.8 across 4 years, with a median of $415653.5 in 2023.
• Across the five-year window, Receivables surged 232.37% in 2023 and surged 41.41% in 2024, its largest moves.
• Year by year, Receivables stood at $103607.0 in 2022, then jumped by 232.37% to $344361.0 in 2023, then jumped by 41.41% to $486946.0 in 2024, then soared by 185.52% to $1.4 million in 2025.
• Per Business Quant data, the three most recent Receivables figures were $1.4 million in Q4 2025, $486946.0 in Q4 2024, and $344361.0 in Q4 2023.